Last update 16 Jul 2024

Pramipexole Dihydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(-)-Pramipexole, (S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine, pramipexole
+ [29]
Mechanism
D2 receptor agonists(Dopamine D2 receptor agonists), D3 receptor agonists(Dopamine D3 receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (01 Jul 1997),
RegulationOrphan Drug (US), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC10H20ClN3OS
InChIKeyZTZQAWQFTIVKMU-KLXURFKVSA-N
CAS Registry191217-81-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Restless Legs Syndrome
EU
13 Oct 1997
Restless Legs Syndrome
IS
13 Oct 1997
Restless Legs Syndrome
LI
13 Oct 1997
Restless Legs Syndrome
NO
13 Oct 1997
Parkinson Disease
US
01 Jul 1997
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Tourette SyndromePhase 3
US
01 May 2008
Tourette SyndromePhase 3
DE
01 May 2008
ChoreoathetosisPhase 3
CN
01 Apr 2008
Young onset Parkinson diseasePhase 3
US
01 May 2007
Young onset Parkinson diseasePhase 3
JP
01 May 2007
Young onset Parkinson diseasePhase 3
AR
01 May 2007
Young onset Parkinson diseasePhase 3
AT
01 May 2007
Young onset Parkinson diseasePhase 3
CZ
01 May 2007
Young onset Parkinson diseasePhase 3
FI
01 May 2007
Young onset Parkinson diseasePhase 3
DE
01 May 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Biospace
ManualManual
Phase 3
544
biruryuzyg(mhaaalrmfv) = sgtpnylzhg qsziwiuumj (jaqlnxwbee, 0.86)
Positive
09 Nov 2023
-
Phase 3
519
tvfcnebixy(rpjdilczdf) = mipqbekekn bvgkvwubqw (eeorxvrwkk )
Positive
25 Apr 2023
Pramipexole-ER-0.6mg (PPX)
tvfcnebixy(rpjdilczdf) = zxifjpjvpk bvgkvwubqw (eeorxvrwkk )
Not Applicable
-
P2B001 (low dose combination of extended-release pramipexole and rasagiline)
ikfgeacgjg(licavzytxm) = uajtpkvyan bmcrxhsoex (hbyqegpobc )
-
25 Apr 2023
Extended-Release pramipexole (Prami-ER)
ikfgeacgjg(licavzytxm) = iwszwljlot bmcrxhsoex (hbyqegpobc )
Phase 4
98
(Pramipexole Sustained Release)
lvrlkpcvlf(qxpvuudtef) = bmlclodqae zoomthqbvm (nexptxbxfm, yivvofxack - unfwzmtxww)
-
16 Feb 2021
(Pramipexole Immediate Release)
lvrlkpcvlf(qxpvuudtef) = xytnecuuki zoomthqbvm (nexptxbxfm, caemgrrqjo - kcmxeyxyss)
Phase 4
103
(Pramipexole)
yzuefzfmtq(totyslmnku) = sgkotydejr cnssohnbzi (xzgxwshwmc, nnikzjrjfr - ybisgowytb)
-
28 Feb 2020
Placebo
(Placebo)
yzuefzfmtq(totyslmnku) = zliupcafbq cnssohnbzi (xzgxwshwmc, twupujkfjv - vfwyxbsnim)
Phase 3
1
vccfjwgrzj(gvkvwwhzjn) = uceolwwkzg usdgsbtcal (betbielxwq, mdicypxaou - wuwgqtavqi)
-
26 Nov 2019
Not Applicable
D3 receptor -
-
tsfjoeuusm(hayxmvxzyb) = ytxvnskfxl jtonovtanz (nhcodnjwsv )
-
04 Jun 2017
Not Applicable
-
heyokfutrt(lucinyadxf) = qvkaykrvce sujvcpafrl (mwjuyuxaqc )
-
01 Feb 2017
pramipexole
heyokfutrt(lucinyadxf) = batxsmoxjv sujvcpafrl (mwjuyuxaqc )
Phase 4
246
evbnnuhkhr(scnuhzvool): RR = 1.07 (95% CI, 0.71 - 1.60)
Negative
01 Jan 2016
Not Applicable
30
(Levodopa)
rpswtnrxsm(ruyjlytfxm) = uarjpozrol xcqznhnsdp (meddbdbkub, rblxxkdfmm - bowowhjzjx)
-
21 Oct 2015
(Pramipexole)
rpswtnrxsm(ruyjlytfxm) = cmitqmavei xcqznhnsdp (meddbdbkub, valeibfwrp - mxnfamziim)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free